Rafael Holdings, Inc. Overview
Pro stress-test →Rafael Holdings primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It is a clinical stage biotechnology company focused on helping patients with difficult to treat diseases.
Strategic Profile
Pro stress-test →The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. With multiple clinical programs ongoing including two Phase 3 trials, the company is transitioning from clinical-stage toward a commercial enterprise.
Competitive Landscape
Pro stress-test →Rafael competes in the early-stage oncology and rare disease therapeutics space against larger pharma companies and clinical-stage biotech peers. The company underperformed the US Pharmaceuticals industry which returned 24.8% over the past year. Differentiation relies on portfolio of metabolic cancer therapies and rare disease treatments, but faces typical biotech execution risks.
Industry Context
Rafael Holdings, Inc. operates in Biotechnology / Pharmaceutical Development.
Key facts
Founded: 2017 · Headquarters: Newark, New Jersey, United States · Employees: Unknown · Revenue: Limited/Early stage · Market cap: $50M-$75M